Wednesday, July 16, 2025 7:30:41 AM
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE) and other pharmaceutical companies that manufacture drugs abroad are expected to be affected immediately, the news outlet reported. Trump recently said tariffs on pharmaceuticals could reach up to 200%, according to the report....
Recent LLY News
- FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions • PR Newswire (US) • 04/01/2026 03:30:00 PM
- Hopes of Iran War Resolution Spark Broad Rally on Wall Street • IH Market News • 03/31/2026 08:31:16 PM
- Alkermes shares jump 13% after Lilly announces sleep-disorder acquisition • IH Market News • 03/31/2026 02:55:46 PM
- Novo Nordisk introduces discounted Wegovy subscription plan in the U.S. • IH Market News • 03/31/2026 02:46:32 PM
- Centessa shares soar after Lilly announces multibillion-dollar acquisition deal • IH Market News • 03/31/2026 02:42:29 PM
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders • PR Newswire (US) • 03/31/2026 10:45:00 AM
- Eli Lilly strikes $2.75 billion drug discovery partnership with InSilico • IH Market News • 03/30/2026 09:33:40 AM
- Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity • PR Newswire (US) • 03/28/2026 07:15:00 PM
- Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis • PR Newswire (US) • 03/27/2026 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 10:02:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:23:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:19:30 PM
- Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes • PR Newswire (US) • 03/19/2026 10:45:00 AM
- Stronger-Than-Expected Inflation Figures Could Pressure Wall Street: Dow Jones, S&P, Nasdaq, Futures • IH Market News • 03/18/2026 01:17:18 PM
- Wall Street seen lower as stronger inflation data clouds outlook before Fed decision: Dow Jones, S&P, Nasdaq, Futures • UK Market News • 03/18/2026 01:17:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:32:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:31:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:30:41 PM
- Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis • PR Newswire (US) • 03/16/2026 10:45:00 AM
- Lilly flags impurity in compounded versions of its weight-loss drug, warns of potential health risks • IH Market News • 03/12/2026 11:01:06 AM
- Eli Lilly plans $3 billion China investment, files for approval of new GLP-1 treatment • IH Market News • 03/11/2026 01:51:37 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/06/2026 09:35:56 PM
- Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients • PR Newswire (US) • 03/05/2026 11:00:00 AM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (Canada) • 03/03/2026 02:00:00 PM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (US) • 03/03/2026 02:00:00 PM
